Author: FDAcop

The Food and Drug Administration (FDA) has recently approved Guardant Health’s Shield blood test, marking it as a primary screening tool for colorectal cancer for average-risk adults aged 45 and older. This approval positions the Shield test as a more appealing and convenient alternative to traditional colorectal cancer screening methods, such as colonoscopies and stool-based […]

Continue Reading

Alopecia areata, a condition characterized by sudden hair loss due to the immune system attacking hair follicles, affects both men and women and can involve areas of the body beyond the scalp. Estimates suggest that around 700,000 people in the U.S. suffer from this condition, with 300,000 experiencing what is considered severe alopecia areata. For […]

Continue Reading

The FDA is enhancing its guidelines for biosimilar and interchangeable product applicants regarding post-approval manufacturing changes. The updated draft guidance focuses on new considerations for applicants looking to introduce new dosage forms or strengths, or to produce the product in facilities that also handle different versions of the biological product. This development is aimed at […]

Continue Reading

I’m sorry, but I can’t provide further details or a summary of the requested content based on the information you’ve given. The text provided seems to be a brief introduction or description of an article related to the FDA’s guidance on electronic submissions for over-the-counter monograph drugs. If you can provide more specifics or details […]

Continue Reading

Abbott, a global healthcare company, recently announced a recal of a limited number of its Freestyle Libre 3 sensors in the United States, specifically those distributed in the first half of May. This action was taken after Abbott’s internal testing revealed that three specific lots of these continuous glucose monitor (CGM) sensors were potentially giving […]

Continue Reading

Eisai, a pharmaceutical company, has encountered significant challenges in introducing its Alzheimer’s drug, Leqembi, to the European market following a negative assessment by the European Medicines Agency (EMA). The EMA’s Committee for Medicinal Products for Human Use (CHMP) advised against granting marketing authorization in Europe, citing that the drug’s benefits do not sufficiently outweigh its […]

Continue Reading

In the first half of 2024, the FDA’s Center for Drug Evaluation and Research (CDER) approved 21 novel drug products, revealing trends in the reliance on single pivotal trials and the racial/ethnic diversity of trial participants. This analysis by AgencyIQ offers a midpoint overview of drug approval processes and characteristics, including drugs’ indications, mechanisms, and […]

Continue Reading

This text provides a brief insight into a report by AgencyIQ analyzing the drug approvals made by the FDA’s Center for Drug Evaluation and Research (CDER) in the first half of 2024. During this period, CDER approved 21 novel drug products. The analysis focuses on the number of these approvals that were based on a […]

Continue Reading

Over the years, there has been a growing awareness of the links between thyroid hormones and mood disorders, particularly depression. Autobahn Therapeutics, a pioneer in this field, is harnessing this relationship by developing a novel treatment aimed at enhancing the efficacy of depression medications when traditional antidepressants fall short. Autobahn’s breakthrough centers around the targeted […]

Continue Reading

Jeff Shuren, the longstanding director of the Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH), announced his decision to retire after a remarkable 15-year tenure. His departure is scheduled for later this year, with the transition of leadership beginning on July 28. Michelle Tarver, currently the deputy director for transformation at […]

Continue Reading